XHKG
0932
Market cap11mUSD
Oct 09, Last price
0.03HKD
1D
-3.33%
1Q
7.41%
Jan 2017
-96.68%
IPO
-95.42%
Name
Shunten International (Holdings) Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shunten International (Holdings) Limited operates as an investment firm, primarily focusing on the marketing, sales, and distribution of health and beauty products and dietary supplements. Its commercial activities extend across Hong Kong, Taiwan, and international markets, offering items under both its proprietary labels and private label brands. Beyond these core operations, the company diversified into property investment, the management of licenses and trademarks, e-commerce promotion, traditional Chinese medical consultations, and health food processing. Additionally, it engages in the sale and distribution of various healthcare items, trades nutritional supplements, and delivers general administrative support services. Founded in 2002, the company was originally known as RM Group Holdings Limited, changing to its current designation in February 2018. Its corporate headquarters are situated in Kwai Chung, Hong Kong.
Key people
Siu Fai Cheung
Executive Chairman of the Board · since 2024
Wai Lok Yeung
Chief Executive Officer · since 2024
Man Lung Chen
Co-Chief Executive Officer, Chief Financial Officer · since 2023
Chief Investment Officer · since 2018
Siu Yu Chong
Sales Director · since 2022
Suet Yin Wong
Marketing Director · since 2022
Chin Yeung Fung
Supply Chain Senior Manager · since 2022
Chi Wai Tsang
Chief Compliance Officer · since 2022
Wun Ting Yeung
Commercial Director · since 2022
Yuk Chi Chan
Company Secretary · since 2021
Tsz Kwan So
Non-Executive Director · since 2023
Jian Mei Dong
Non-Executive Independent Director
Chik Shun Lam
Non-Executive Independent Director · since 2024
Kwan Yau Leung
Non-Executive Independent Director · since 2016
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||